Education
About Us
Working with TipRanks
Follow Us
Kuros Biosciences (CH:KURN)
:KURN
RESEARCH TOOLSreports
Total Valuation
Kuros Biosciences has a market cap or net worth of CHF983.17M. The enterprise value is CHF781.22M.
Market CapCHF983.17M
Enterprise ValueCHF781.22M
Share Statistics
Kuros Biosciences has 38,589,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38,589,950
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kuros Biosciences’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -8.65%.
Return on Equity (ROE)-0.06
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-8.65%
Return on Capital Employed (ROCE)-0.08
Revenue Per Employee619.30K
Profits Per Employee-32.13K
Employee Count122
Asset Turnover0.89
Inventory Turnover1.43
Valuation Ratios
The current PE Ratio of Kuros Biosciences is ―. Kuros Biosciences’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value13.52
Price to FCF0.00
Price to Operating Cash Flow352.60
PEG Ratio―
Income Statement
In the last 12 months, Kuros Biosciences had revenue of 75.56M and earned -3.72M in profits. Earnings per share was -0.10.
Revenue75.56M
Gross Profit62.03M
Operating Income-5.00M
Pretax Income-3.35M
Net Income-3.72M
EBITDA-561.00K
Earnings Per Share (EPS)-0.10
Cash Flow
In the last 12 months, operating cash flow was 3.14M and capital expenditures -1.11M, giving a free cash flow of 2.03M billion.
Operating Cash Flow3.14M
Free Cash Flow2.03M
Free Cash Flow per Share0.05
Dividends & Yields
Kuros Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.45
52-Week Price Change120.03%
50-Day Moving Average27.32
200-Day Moving Average23.62
Relative Strength Index (RSI)43.49
Average Volume (3m)258.09K
Important Dates
Kuros Biosciences upcoming earnings date is Aug 14, 2025, TBA (Confirmed).
Last Earnings DateMar 11, 2025
Next Earnings DateAug 14, 2025
Ex-Dividend Date―
Financial Position
Kuros Biosciences as a current ratio of 2.14, with Debt / Equity ratio of 3.05%
Current Ratio2.14
Quick Ratio1.69
Debt to Market Cap0.00
Net Debt to EBITDA27.93
Interest Coverage Ratio-33.52
Taxes
In the past 12 months, Kuros Biosciences has paid 370.00K in taxes.
Income Tax370.00K
Effective Tax Rate-0.11
Enterprise Valuation
Kuros Biosciences EV to EBITDA ratio is -1.39K, with an EV/FCF ratio of 383.89.
EV to Sales10.30
EV to EBITDA-1.39K
EV to Free Cash Flow383.89
EV to Operating Cash Flow247.94
Balance Sheet
Kuros Biosciences has CHF17.46M in cash and marketable securities with CHF1.79M in debt, giving a net cash position of -CHF15.67M billion.
Cash & Marketable SecuritiesCHF17.46M
Total DebtCHF1.79M
Net Cash-CHF15.67M
Net Cash Per Share-CHF0.41
Tangible Book Value Per ShareCHF0.65
Margins
Gross margin is 87.98%, with operating margin of -6.61%, and net profit margin of -4.92%.
Gross Margin87.98%
Operating Margin-6.61%
Pretax Margin-4.43%
Net Profit Margin-4.92%
EBITDA Margin-0.74%
EBIT Margin-4.23%
Analyst Forecast
The average price target for Kuros Biosciences is CHF32.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF32.50
Price Target Upside19.66% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast125.11%
EPS Growth Forecast69.27%